Late Breaking Abstract - Real-World Characteristics of Patients Receiving Dupilumab in Routine Clinical Practice in a Multinational, Non-Interventional Study (ProVENT)

Background: Dupilumab (DPL), a human monoclonal antibody, blocks the shared receptor component of interleukin-4/13, key and central drivers of type 2 (T2) inflammation. In the EU, DPL is approved for treatment of uncontrolled, severe asthma. However, little is known about characteristics of asthma patients (pts) receiving DPL. ProVENT is a non-interventional real-world study, enrolling pts in Germany, Switzerland, and Austria since February 2020. Aim: To assess baseline (BL) characteristics in pts with T2 asthma receiving DPL, including demographics, use-patterns of DPL, efficacy, asthma control, previous therapy, T2 comorbidities, and biomarker (BM) levels (blood eosinophils, fractional exhaled nitric oxide [FeNO], and IgE). Results: BL characteristics of 99 pts currently enrolled in ProVENT are shown (Table). Elevated T2 BMs were common, 63.6% of pts had ongoing T2 comorbidities, and 17.2% received a biologic in the 24 months prior. Conclusion: In this real-world study, a majority of asthma pts had elevated T2 BMs, high exacerbation rates in the year prior, and poor quality of life. DPL was the first biologic in most of the patients. Interestingly, a large proportion of pts with uncontrolled severe asthma eligible for biologics in Germany are still being treated by primary care physicians.